ExploreWatchlistsPricing
  1. JP-listed companies
  2. BrightPath Biotherapeutics Co., Ltd.
  3. Financials
  4. Cash from financing

BrightPath Biotherapeutics Co., Ltd. (4594)

Market cap
¥4.9B
P/E ratio
-3.9x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from financing (Million JPY)YoY (%)
Mar 31, 20262,714+170.04%
Mar 31, 20251,005+45.43%
Mar 31, 2024691+59.91%
Mar 31, 2023432-24.09%
Mar 31, 2022569-72.27%
Mar 31, 20212,053+23994.47%
Mar 31, 20209-46.10%
Mar 31, 201916-99.52%
Mar 31, 20183,281-7.81%
Mar 31, 20173,559+33.18%
Mar 31, 20162,673+114.20%
Mar 31, 20151,248

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat